TY - JOUR
T1 - Innovation capacity in the healthcare sector and historical anchors
T2 - examples from the UK, Switzerland and the US
AU - Lawton Smith, Helen
AU - Bagchi-Sen, Sharmistha
AU - Edmunds, Laurel
N1 - Funding Information:
We thank John Slater for his comments on an earlier version of this paper. Laurel Edmunds is supported by the NIHR Oxford BRC.
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Innovation is an integral part of economic development in developed economies. In the post 2008 period, a key policy agenda is that of sustainable development, which calls for innovation in all aspects of value-chains. In this paper, we focus on innovation from the biotech—pharma perspective to see whether or not this will lead to a sustainable future for the regions where there are clusters of firms in this sector. We examine data from a recently completed European Union study of innovation in the Healthcare sector from the UK and Switzerland, countries with an historical base in pharma, to understand how innovation pathways vary at the regional level in the broader life sciences, which incorporate biotech and more. Innovation in the healthcare sector in two regions, Oxfordshire in the UK and Zurich in Switzerland are compared. We contextualize our discussion by drawing on studies that focus on the sector in the US, specifically Boston. The analytical framework comprises three elements: innovation systems and national and regional economic development theories are the first two, followed by approaches which consider organizational or institutional activity. This framework is used to help explain and understand the complexity of how innovation is organized at the sub-national level. The overall context is that it is increasing becoming a condition for government financing of research that it has more immediate application in industry or have the possibility of commercialisation (e.g., translational research).
AB - Innovation is an integral part of economic development in developed economies. In the post 2008 period, a key policy agenda is that of sustainable development, which calls for innovation in all aspects of value-chains. In this paper, we focus on innovation from the biotech—pharma perspective to see whether or not this will lead to a sustainable future for the regions where there are clusters of firms in this sector. We examine data from a recently completed European Union study of innovation in the Healthcare sector from the UK and Switzerland, countries with an historical base in pharma, to understand how innovation pathways vary at the regional level in the broader life sciences, which incorporate biotech and more. Innovation in the healthcare sector in two regions, Oxfordshire in the UK and Zurich in Switzerland are compared. We contextualize our discussion by drawing on studies that focus on the sector in the US, specifically Boston. The analytical framework comprises three elements: innovation systems and national and regional economic development theories are the first two, followed by approaches which consider organizational or institutional activity. This framework is used to help explain and understand the complexity of how innovation is organized at the sub-national level. The overall context is that it is increasing becoming a condition for government financing of research that it has more immediate application in industry or have the possibility of commercialisation (e.g., translational research).
KW - Biotech
KW - Boston
KW - Innovation
KW - Oxfordshire
KW - Regional development
KW - Zurich
UR - http://www.scopus.com/inward/record.url?scp=84944710982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944710982&partnerID=8YFLogxK
U2 - 10.1007/s10961-015-9442-7
DO - 10.1007/s10961-015-9442-7
M3 - Article
AN - SCOPUS:84944710982
SN - 0892-9912
VL - 41
SP - 1420
EP - 1439
JO - Journal of Technology Transfer
JF - Journal of Technology Transfer
IS - 6
ER -